201 related articles for article (PubMed ID: 19930745)
1. [Rosiglitazone: no increase in cardiovascular mortality].
Jazet IM; Meinders AE
Ned Tijdschr Geneeskd; 2009; 153():A942. PubMed ID: 19930745
[TBL] [Abstract][Full Text] [Related]
2. Rosiglitazone and outcomes for patients with diabetes mellitus and coronary artery disease in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial.
Bach RG; Brooks MM; Lombardero M; Genuth S; Donner TW; Garber A; Kennedy L; Monrad ES; Pop-Busui R; Kelsey SF; Frye RL;
Circulation; 2013 Aug; 128(8):785-94. PubMed ID: 23857320
[TBL] [Abstract][Full Text] [Related]
3. Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis.
Singh S; Loke YK; Furberg CD
JAMA; 2007 Sep; 298(10):1189-95. PubMed ID: 17848653
[TBL] [Abstract][Full Text] [Related]
4. Rosiglitazone evaluated for cardiovascular outcomes--an interim analysis.
Home PD; Pocock SJ; Beck-Nielsen H; Gomis R; Hanefeld M; Jones NP; Komajda M; McMurray JJ;
N Engl J Med; 2007 Jul; 357(1):28-38. PubMed ID: 17551159
[TBL] [Abstract][Full Text] [Related]
5. Database evaluation of the effects of long-term rosiglitazone treatment on cardiovascular outcomes in patients with type 2 diabetes.
Loebstein R; Dushinat M; Vesterman-Landes J; Silverman B; Friedman N; Katzir I; Kurnik D; Lomnicky Y; Kokia E; Halkin H
J Clin Pharmacol; 2011 Feb; 51(2):173-80. PubMed ID: 20484611
[TBL] [Abstract][Full Text] [Related]
6. Was there really any evidence that rosiglitazone increased the risk of myocardial infarction or death from cardiovascular causes?
Stone JC; Furuya-Kanamori L; Barendregt JJ; Doi SA
Pharmacoepidemiol Drug Saf; 2015 Mar; 24(3):223-7. PubMed ID: 25515780
[TBL] [Abstract][Full Text] [Related]
7. Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes (RECORD): study design and protocol.
Home PD; Pocock SJ; Beck-Nielsen H; Gomis R; Hanefeld M; Dargie H; Komajda M; Gubb J; Biswas N; Jones NP
Diabetologia; 2005 Sep; 48(9):1726-35. PubMed ID: 16025252
[TBL] [Abstract][Full Text] [Related]
8. The safety of rosiglitazone in the treatment of type 2 diabetes.
Singh S; Loke YK
Expert Opin Drug Saf; 2008 Sep; 7(5):579-85. PubMed ID: 18759710
[TBL] [Abstract][Full Text] [Related]
9. Meta-analysis of rare events: an update and sensitivity analysis of cardiovascular events in randomized trials of rosiglitazone.
Dahabreh IJ; Economopoulos K
Clin Trials; 2008; 5(2):116-20. PubMed ID: 18375649
[TBL] [Abstract][Full Text] [Related]
10. The thiazolidinediones rosiglitazone and pioglitazone and the risk of coronary heart disease: a retrospective cohort study using a US health insurance database.
Ziyadeh N; McAfee AT; Koro C; Landon J; Arnold Chan K
Clin Ther; 2009 Nov; 31(11):2665-77. PubMed ID: 20110009
[TBL] [Abstract][Full Text] [Related]
11. Response to letter regarding article, "rosiglitazone and outcomes for patients with diabetes mellitus and coronary artery disease in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial".
Bach RG; Brooks MM; Lombardero M; Genuth S; Donner TW; Garber A; Kennedy L; Monrad ES; Pop-Busui R; Kelsey SF; Frye RL;
Circulation; 2014 Apr; 129(16):e460-1. PubMed ID: 24753557
[No Abstract] [Full Text] [Related]
12. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
Plosker GL; Figgitt DP
Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
[TBL] [Abstract][Full Text] [Related]
13. Thiazolidinediones in type 2 diabetes: a cardiology perspective.
Khanderia U; Pop-Busui R; Eagle KA
Ann Pharmacother; 2008 Oct; 42(10):1466-74. PubMed ID: 18698014
[TBL] [Abstract][Full Text] [Related]
14. Comparative risk of major cardiovascular events associated with second-line antidiabetic treatments: a retrospective cohort study using UK primary care data linked to hospitalization and mortality records.
Zghebi SS; Steinke DT; Rutter MK; Emsley RA; Ashcroft DM
Diabetes Obes Metab; 2016 Sep; 18(9):916-24. PubMed ID: 27177784
[TBL] [Abstract][Full Text] [Related]
15. Uncertain effects of rosiglitazone on the risk for myocardial infarction and cardiovascular death.
Diamond GA; Bax L; Kaul S
Ann Intern Med; 2007 Oct; 147(8):578-81. PubMed ID: 17679700
[TBL] [Abstract][Full Text] [Related]
16. Relationship between thiazolidinedione use and cardiovascular outcomes and all-cause mortality among patients with diabetes: a time-updated propensity analysis.
Habib ZA; Tzogias L; Havstad SL; Wells K; Divine G; Lanfear DE; Tang J; Krajenta R; Pladevall M; Williams LK
Pharmacoepidemiol Drug Saf; 2009 Jun; 18(6):437-47. PubMed ID: 19235778
[TBL] [Abstract][Full Text] [Related]
17. Incidence of cardiovascular events in which 2 thiazolidinediones are used as add-on treatments for type 2 diabetes mellitus in a Taiwanese population.
Wang CC; Chen WL; Kao TW; Chang YW; Loh CH; Chou CC
Clin Ther; 2011 Dec; 33(12):1904-13. PubMed ID: 22118894
[TBL] [Abstract][Full Text] [Related]
18. Coronary heart disease outcomes in patients receiving antidiabetic agents.
McAfee AT; Koro C; Landon J; Ziyadeh N; Walker AM
Pharmacoepidemiol Drug Saf; 2007 Jul; 16(7):711-25. PubMed ID: 17551989
[TBL] [Abstract][Full Text] [Related]
19. Results of a reevaluation of cardiovascular outcomes in the RECORD trial.
Mahaffey KW; Hafley G; Dickerson S; Burns S; Tourt-Uhlig S; White J; Newby LK; Komajda M; McMurray J; Bigelow R; Home PD; Lopes RD
Am Heart J; 2013 Aug; 166(2):240-249.e1. PubMed ID: 23895806
[TBL] [Abstract][Full Text] [Related]
20. Cardiovascular risk and cardiometabolic protection: role of glitazones.
Petrazzi L; Grassi D; Polidoro L; D'Aurelio A; Croce G; Properzi G; Tiberti S; Desideri G; Ferri C
J Nephrol; 2008; 21(6):826-35. PubMed ID: 19034866
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]